Feedback plc is a sub-£3m AIM MedTech whose Bleepa messaging platform has quietly embedded itself in the NHS. With a national funding bid pending and cash into mid-2027, the question is whether commercial scale finally arrives.
Introduction
Feedback plc (LSE:FBDK), once known chiefly for medical-imaging software, is today one of the London market's smallest healthcare-technology companies, valued at under £3m. Yet its clinical-communications platform, Bleepa, has quietly threaded itself into the plumbing of the National Health Service, from cancer pathways to referral systems. That contrast, a tiny valuation against genuine NHS integration, is what makes the stock intriguing right now, particularly with a national funding decision hanging in the balance. The central question for investors is straightforward but difficult to answer: is there a much larger digital-healthcare Business hiding inside this micro-cap, or is Feedback a perennially promising story that never quite converts NHS interest into Revenue at scale?
The Company
Feedback plc (AIM: FDBK), which trades as Feedback Medical, develops software for the NHS. Its flagship product, Bleepa, is a medical-grade clinical-communications platform: a secure, regulated messaging and image-sharing tool that lets clinicians discuss cases, view diagnostic images and coordinate care across organisational boundaries. Alongside it sits CareLocker, a cloud-based architecture for storing and sharing patient records built around the individual patient rather than a single institution.
The company targets NHS pathway redesign, shifting diagnostics and referrals out of hospitals and into community settings. Bleepa now generates roughly 89% of group revenue. To concentrate resources on the UK, Feedback has paused its Indian operations. Its competitors range from entrenched electronic patient record (EPR) vendors and secure-messaging apps to systems the NHS builds in-house, a crowded field for a company of Feedback's size.
Why the Stock Is in Focus
The share is in focus because of a single, potentially transformational catalyst: a national business case for Bleepa submitted under the NHS Spending Review, the outcome of which remains pending and, the company says, could lead to material national or regional adoption. Underpinning that bid, Feedback reported concrete progress through 2025-26.
It completed integrations with core NHS infrastructure, including the e-Referral Service, the Personal Demographics Service and GP Connect. A Non-Site-Specific Symptoms cancer pathway went live in the Sussex Integrated Care System, and Feedback was selected to support the government's two national simulations of the proposed Neighbourhood Health Service. Management argues that the NHS 10-Year Plan, with its stated shift toward community, digital-first and neighbourhood care, aligns closely with what Bleepa does. The company has also said it is in late-stage discussions on strategic partnerships with consulting, cloud and technology firms.
Financial Position
Feedback remains deeply loss-making and pre-scale. For the year to 31 May 2025, revenue fell about 25% to £0.89m (FY2024: £1.18m), reflecting delayed NHS procurement and non-recurring prior-year work. The reported loss after tax widened to £7.32m, although that figure included a £3.19m non-cash Impairment of intangible assets; the adjusted EBITDA loss was £3.06m.
In the half-year to 30 November 2025, revenue was broadly flat at £0.41m (H1 prior year: £0.45m), while the adjusted EBITDA loss widened to £1.61m as the company hired staff and invested in cloud technology. Cash stood at £3.82m at 30 November 2025, down from £7.26m a year earlier, which management says provides a runway into mid-2027. A £6.1m gross placing in November 2024 funded the current push. The Market Capitalisation is roughly £3m at about 6.7p, against a 52-week range of 6.5p to 15p. No Dividend is paid.
Bull Case
The bull case rests on optionality. Feedback has spent years and considerable capital embedding Bleepa into NHS workflows, and those integrations are now largely complete, a barrier rivals cannot replicate quickly. If the national business case is approved, even a partial national or regional roll-out would dwarf current revenue and could sharply re-rate a company valued at barely £3m. The policy backdrop is supportive: the NHS 10-Year Plan explicitly prioritises the neighbourhood-care, digital model Feedback is built around. Strategic partnerships with larger technology or consulting firms could add distribution reach and credibility. For risk-tolerant investors, the potential payoff profile is highly asymmetric relative to the tiny market value.
Bear Case and Risks
The bear case is equally stark. Feedback's fortunes hinge almost entirely on NHS procurement, which has repeatedly slipped; a key roll-out decision has been delayed more than once, and the Spending Review outcome is outside the company's control. Revenue remains tiny and is not growing, while losses are widening. With £3.82m of cash and a burn that consumed roughly half its cash over the year, a further fundraising before revenue scales looks plausible, and at a sub-£3m valuation any placing would be heavily dilutive to existing holders. As a micro-cap, the shares are Illiquid and volatile. Customer concentration, competition from entrenched EPR vendors and the risk of tighter NHS budgets all weigh on the story.
What Investors Should Watch Next
The single most important milestone is the outcome of the national Bleepa business case under the NHS Spending Review; any decision, whose timing is unconfirmed, is the swing Factor for the shares. Beyond that, watch for the conversion of the Sussex cancer pathway and the Neighbourhood Health Service simulations into paid, recurring contracts; the naming of a strategic partner from the late-stage discussions; the next full-year results, for the year to 31 May 2026, typically published in the autumn; and any updated commentary on cash runway or fresh funding. Evidence of accelerating Recurring Revenue would be the clearest sign that the larger story is becoming real.
Conclusion
So is this tiny medtech hiding a much bigger digital-healthcare story? The honest answer is: potentially, but it is not yet proven. Feedback has done the unglamorous work of wiring Bleepa into the NHS, and the policy direction is genuinely in its favour, so the raw materials of a larger business do exist. What is missing is commercial scale: revenue is still below £1m, losses are widening, and the transformational catalyst sits with NHS decision-makers who have repeatedly moved slowly. Until a national or regional roll-out is signed and recurring revenue begins to build, the bigger story remains an aspiration backed by real groundwork rather than an established fact. Investors should watch the Spending Review outcome and the cash runway above all else.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...